The new semaglutide vs resmetirom study, announced by Novo Nordisk on November 6, 2026, doesn't tell us which medicine is better for the liver. Semaglutide users had larger drops in weight and AST, an enzyme measured in blood to track liver-cell injury. Resmetirom users had larger drops in LDL cholesterol, the type that can build up in arteries. Another liver enzyme, ALT, showed no clear difference.

Those findings don't show which medicine prevents more scarring or helps people live longer.

Semaglutide vs resmetirom: what happened

As of November 20, 2026, the day this article was written, Novo Nordisk's November 6 announcement reports two health-records studies presented at The Liver Meeting, an annual liver-research conference.

Both concern MASH, short for metabolic dysfunction-associated steatohepatitis: liver fat with inflammation and liver-cell injury. Its older name was NASH, or nonalcoholic steatohepatitis. Fibrosis means scarring that can follow that injury.

PLATINUM-Truveta compared 2,873 adults starting semaglutide 2.4 mg with 2,285 starting resmetirom. The six-month changes reported in the release were:

Average change at six months Semaglutide Resmetirom
AST, units per liter of blood −10.4 −4.5
ALT, units per liter of blood −14.8 −11.6
Body weight, pounds −18.9 −5.6

The analysis found clear AST and weight differences. The ALT gap was not statistically significant: the analysis could not reliably separate that difference from chance. LDL cholesterol fell more with resmetirom.

These are weighted averages, recalculated to make the groups more comparable. They aren't predictions for one person. The public conference poster supports the same overall findings.

Novo Nordisk funded the research and makes semaglutide. These findings come from conference reports and a sponsor's release, rather than a full peer-reviewed journal report.

What RHODIUM-2 adds

The second analysis, RHODIUM-2, asked a different question. It compared 2,479 adults starting semaglutide with 70,702 adults who did not start it.

According to the same November 6 release, semaglutide starters had larger reductions in both liver enzymes and weight after 12 months. Their average blood-sugar measure also fell more. That measure, HbA1c, reflects blood sugar over roughly three months.

This was not another semaglutide-versus-resmetirom comparison. It adds information about semaglutide in routine care, but cannot identify which of the two medicines is better.

What this means for someone with MASH

The medicines work differently. Semaglutide acts like GLP-1, a gut hormone involved in fullness and blood-sugar control. Resmetirom, sold as Rezdiffra, is a daily pill. It activates thyroid hormone receptor-beta, a switch in liver cells involved in handling fat.

Rezdiffra became the first U.S. medicine authorized for this liver disease on March 14, 2024. Its prescribing information, revised July 2026, covers adults with MASH and moderate to advanced scarring, stages F2–F3, without cirrhosis. Cirrhosis means the most advanced stage of scarring.

Wegovy injection gained its MASH indication on August 15, 2025. Its label, revised June 2026, covers adults with noncirrhotic MASH and F2–F3 scarring, alongside a reduced-calorie diet and increased physical activity.

Both liver indications use accelerated approval: permission based on earlier measures while further studies test lasting clinical benefit. The broader semaglutide for fatty liver evidence concerns a defined diagnosis and disease stage, rather than everyone with liver fat.

What the comparison cannot tell us

People weren't assigned a medicine by chance. The poster shows that semaglutide users started younger and heavier. Adjustments can balance recorded differences, but cannot remove differences the records never captured.

Follow-up analyses required continued treatment and available repeat measurements. That can favor people able to stay on treatment. Six months also says little about a disease that can progress over years.

PLATINUM measured blood tests and weight, not liver biopsies, scarring progression, cirrhosis or survival. A biopsy is a small tissue sample. The separate ESSENCE biopsy trial, reported in NEJM in 2025, compared semaglutide with placebo, an inactive treatment. It did not compare semaglutide with resmetirom.

Tirzepatide's liver evidence is separate too. Its SYNERGY-NASH trial, published in NEJM in 2024, compared tirzepatide with placebo. It cannot rank these two medicines or establish the same results for a compounded preparation.

Safety still belongs in the comparison

Blood-test changes don't establish which medicine is safer. The two labels have different warnings and medication interactions.

Wegovy carries a boxed warning, the most serious kind of label warning, for risk of thyroid C-cell tumors. It is contraindicated, meaning it must not be used, with a personal or family history of medullary thyroid carcinoma, a type of thyroid cancer. That also applies to multiple endocrine neoplasia type 2, an inherited condition that causes tumors.

Its label says to stop using Wegovy and call a healthcare provider right away for severe stomach pain that does not go away. That warning applies with or without nausea or vomiting. Such pain can signal pancreatitis, meaning inflammation of the pancreas.

The Rezdiffra label calls for liver-test monitoring and discontinuing the medicine if liver injury is suspected. It also limits doses of certain statins, medicines used to lower cholesterol. A favorable average blood-test result does not cancel those safety rules.

What changes for a compounded prescription

Wegovy's MASH indication belongs to that branded product. It does not extend to compounded semaglutide, and neither records study tested a compounded preparation.

Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

A licensed provider may still prescribe — that decision is between you and your doctor.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The prescriber sets the actual dose and follow-up plan.

What to watch next

There is no published randomized trial, which assigns treatment by chance, directly comparing semaglutide and resmetirom for MASH. A useful next step would be a full journal report, with follow-up counts, safety results and more detail about remaining differences between groups.

Longer studies need to answer whether fewer people develop cirrhosis, need a transplant or die. Falling liver enzymes alone cannot answer those questions.

As of November 20, 2026, the day this article was written, European guidance published September 29, 2026 recommends choosing treatment around the person's risks, preferences and other health conditions. That includes weight, diabetes, heart disease and kidney disease.

Different populations matter too. The tesamorelin fatty liver trial enrolled people with HIV, a virus that weakens the immune system. Its findings answer another question entirely.

For a visit, the useful question is which evidence matches the person's liver diagnosis and overall health. This conference comparison doesn't settle that choice.